{"id":"NCT02409667","sponsor":"Novartis Pharmaceuticals","briefTitle":"Plaque Psoriasis Efficacy and Safety With Secukinumab","officialTitle":"Long Term Clear Skin Maintenance Treatment Optimization in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Multicenter, Open-label With Blinded-assessment, Comparative, 52 Week Study to Evaluate the Efficacy, Safety and Tolerability of Secukinumab 300 mg s.c.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-05-07","primaryCompletion":"2017-03-14","completion":"2017-05-08","firstPosted":"2015-04-07","resultsPosted":"2019-05-13","lastUpdate":"2019-05-13"},"enrollment":16487,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Plaque Psoriasis"],"interventions":[{"type":"BIOLOGICAL","name":"Secukinumab","otherNames":[]}],"arms":[{"label":"Secukinumab 300mg in PASI 90 responders (every 4 weeks)","type":"ACTIVE_COMPARATOR"},{"label":"Secukinumab 300mg in PASI 90 responders (longer intervals)","type":"EXPERIMENTAL"},{"label":"Secukinumab 300mg in PASI 75-90 responders (every 4 weeks)","type":"EXPERIMENTAL"},{"label":"Secukinumab 300mg in PASI 75-90 responders (shorter intervals)","type":"ACTIVE_COMPARATOR"}],"summary":"To demonstrate in the patient pool of PASI 90 responders at Week 24 that secukinumab 300 mg s.c. when administered at a longer dosing interval is non-inferior to secukinumab 300 mg s.c. every 4 weeks treatment with respect to maintaining a PASI 90 response rate at Week 52.","primaryOutcome":{"measure":"Maintenance of PASI 90 Response at Week 52 in Participants With a PASI 90 Response at Week 24","timeFrame":"Week 52","effectByArm":[{"arm":"Treatment Period 2: Group 1","deltaMin":552,"sd":null},{"arm":"Treatment Period 2: Group 2","deltaMin":496,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.1499"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":200,"countries":["Austria","Belgium","Bulgaria","Croatia","Czechia","Denmark","Finland","France","Germany","Greece","Hungary","Israel","Italy","Latvia","Lithuania","Netherlands","Poland","Portugal","Russia","Slovakia","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":73,"n":1647},"commonTop":["Viral upper respiratory tract infection","Headache","Diarrhoea","Back pain","Upper respiratory tract infection"]}}